Holen Sie sich die Stockscreener-App
4.84
1.47%
0.07
Vorhandelsmarkt:
4.88
0.04
+0.83%
Schlusskurs vom Vortag:
$4.77
Offen:
$4.81
24-Stunden-Volumen:
21.28M
Relative Volume:
0.90
Marktkapitalisierung:
$2.07B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.1226
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
+2.98%
1M Leistung:
-16.12%
6M Leistung:
-23.78%
1J Leistung:
-27.22%
1-Tages-Spanne:
$4.6601
$4.92
1-Wochen-Bereich:
$4.51
$5.09
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.84 | 2.08B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 4,149,346 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Short Squeeze: What are analysts price targets for Recursion Pharmaceuticals IncJuly 2025 Levels & Free Safe Entry Trade Signal Reports - خودرو بانک
Aug PostEarnings: Is Recursion Pharmaceuticals Inc forming a double bottom2025 Price Momentum & AI Powered Trade Plan Recommendations - خودرو بانک
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLC - MarketBeat
Goldman Sachs Group Inc. Sells 481,645 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Needham, known as a 'biotech stock picker,' is betting on this leader in 'AI + drug discovery,' forecasting a 68% surge in its stock price. - 富途牛牛
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.7%Should You Buy? - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Recursion Pharmaceuticals (RXRX): How Recent Drug Development Moves and Investor Outreach Shape Valuation - Sahm
Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - Yahoo Finance
Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX) - MarketBeat
Market Fear: Can Recursion Pharmaceuticals Inc. expand into new marketsWeekly Market Outlook & Weekly Momentum Stock Picks - خودرو بانک
Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc. - MarketBeat
Is Recursion Pharmaceuticals (NASDAQ:RXRX) Using Debt In A Risky Way? - 富途牛牛
Recursion Pharmaceuticals Stock: An Exponential Climb? - timothysykes.com
Will Recursion Pharmaceuticals Rise or Fall? - StocksToTrade
RXRX’s Market Strategy: Analyzing Recent Developments - timothysykes.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Pipeline Updates - Quiver Quantitative
Oversold Conditions For Recursion Pharmaceuticals (RXRX) - Nasdaq
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Russell Investments Group Ltd. Has $206,000 Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is Recursion Pharmaceuticals Inc. forming a breakout patternJuly 2025 Big Picture & AI Forecast for Swing Trade Picks - beatles.ru
Ranking Recursion Pharmaceuticals Inc. among high performing stocks via toolsSwing Trade & Daily Price Action Insights - Newser
Tools to assess Recursion Pharmaceuticals Inc.’s risk profileJuly 2025 Opening Moves & Consistent Income Trade Ideas - Newser
Published on: 2025-09-08 04:20:29 - Newser
Applying Wyckoff theory to Recursion Pharmaceuticals Inc. stockQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Using Ichimoku Cloud for Recursion Pharmaceuticals Inc. technicalsEarnings Trend Report & Precise Swing Trade Entry Alerts - Newser
Analyzing recovery setups for Recursion Pharmaceuticals Inc. investors2025 AllTime Highs & Real-Time Chart Breakout Alerts - Newser
Real time alert setup for Recursion Pharmaceuticals Inc. performanceBond Market & Free Community Consensus Stock Picks - Newser
Detecting support and resistance levels for Recursion Pharmaceuticals Inc.CEO Change & High Win Rate Trade Tips - Newser
Multi asset correlation models including Recursion Pharmaceuticals Inc.2025 Pullback Review & Expert Approved Momentum Ideas - Newser
How to read the order book for Recursion Pharmaceuticals Inc.Market Weekly Review & Verified Swing Trading Watchlist - Newser
Will Recursion Pharmaceuticals Inc. stock recover after recent drop2025 Technical Patterns & Reliable Price Action Trade Plans - Newser
Historical volatility pattern of Recursion Pharmaceuticals Inc. visualizedGold Moves & Weekly Chart Analysis and Guides - Newser
Volatility clustering patterns for Recursion Pharmaceuticals IncJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
Chart based exit strategy for Recursion Pharmaceuticals Inc.2025 Institutional Moves & Real-Time Volume Analysis - Newser
Recursion Pharmaceuticals Inc. stock prediction for this weekJuly 2025 Big Picture & Weekly Market Pulse Updates - Newser
Can Recursion Pharmaceuticals Inc. rally from current levels2025 Price Momentum & AI Forecasted Entry and Exit Points - Newser
How to escape a deep drawdown in Recursion Pharmaceuticals Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - Newser
S P Trends: Will Recursion Pharmaceuticals Inc. outperform tech stocksRecession Risk & Technical Entry and Exit Alerts - خودرو بانک
What’s the recovery path for long term holders of Recursion Pharmaceuticals Inc.Quarterly Profit Report & Risk Managed Investment Strategies - Newser
Will Recursion Pharmaceuticals Inc. see short term momentumIPO Watch & Real-Time Chart Pattern Alerts - Newser
Will Recursion Pharmaceuticals Inc. benefit from current market trends2025 Risk Factors & High Accuracy Swing Trade Signals - خودرو بانک
Is Recursion Pharmaceuticals Inc. in a long term uptrendInsider Buying & Safe Capital Growth Trade Ideas - خودرو بانک
Will Recursion Pharmaceuticals Inc. benefit from macro trendsMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Applying chart zones and confluence areas to Recursion Pharmaceuticals Inc.2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
Forecasting Recursion Pharmaceuticals Inc. price range with options dataWeekly Profit Summary & Weekly High Conviction Trade Ideas - Newser
Is Recursion Pharmaceuticals Inc. a strong growth stockJuly 2025 Trade Ideas & Consistent Growth Equity Picks - خودرو بانک
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):